Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
CagriSema shows significant improvements in HbA1c and body weight compared to placebo, but its advantages over semaglutide are less clear, particularly for HbA1c.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
This study evaluated the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide, in individuals with Type 2 diabetes. The analysis included six trials with a total of 4554 participants, focusing on HbA1c and body weight changes. Compared to placebo, CagriSema 2.4 mg resulted in significant reductions in both HbA1c and body weight.
Abstract
<h4>Background</h4>CagriSema combines cagrilintide with semaglutide and may improve glycaemic control and body weight in Type 2 diabetes. We evaluated its dose- and comparator-specific efficacy and safety.<h4>Methods</h4>PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched through 30 June 2026 for randomized controlled trials. Analyses were stratified by CagriSema dose and comparator. For HbA1c and body weight, efficacy/trial-product estimands were aligned where sufficiently reported, with treatment-policy estimates examined in sensitivity analyses. Bayesian random-effects models generated posterior medians and 95% credible intervals (CrIs).<h4>Results</h4>Six trials representing 4554 potentially eligible participants with Type 2 diabetes were included. Compared with placebo, CagriSema 2.4 mg produced between-group differences of -1.87 percentage points in HbA1c (95% CrI, -2.08 to -1.62) and -12.69 percentage points in percentage body-weight change (95% CrI, -13.78 to -11.61). Versus semaglutide 2.4 mg, the additional HbA1c reduction was modest and uncertain (-0.21 percentage points; 95% CrI, -0.62 to 0.11), whereas additional body-weight reduction remained probable (-5.84 percentage points; 95% CrI, -10.08 to -2.15). Gastrointestinal adverse events and adverse-event-related discontinuation were increased versus placebo (RR, 2.27 [95% CrI, 1.81 - 3.00] and 3.16 [1.50 to 6.87], respectively), while estimates versus semaglutide were less precise.<h4>Conclusions</h4>CagriSema provides substantial glycaemic and body-weight benefits versus placebo. Its incremental advantage over dose-matched semaglutide is more evident for body-weight reduction, while comparative gastrointestinal tolerability and discontinuation risk remain uncertain.
Background
This paper addresses the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide, in improving glycaemic control and body weight in Type 2 diabetes. Previous studies have shown that both cagrilintide and semaglutide can improve glycaemic control, but the specific benefits of their combination were not well established. This systematic review and meta-analysis aims to clarify the dose- and comparator-specific effects of CagriSema.
Methods
The study utilized a systematic review and Bayesian meta-analysis of randomized controlled trials, searching databases such as PubMed, Embase, and ClinicalTrials.gov up to June 30, 2026. A total of six trials were included, representing 4554 potentially eligible participants with Type 2 diabetes. The primary outcomes measured were HbA1c and body weight, with analyses stratified by CagriSema dose and comparator.
Results
The primary endpoint showed that CagriSema 2.4 mg produced a reduction of -1.87 percentage points in HbA1c compared to placebo (95% CrI, -2.08 to -1.62). Additionally, there was a body weight change of -12.69 percentage points compared to placebo (95% CrI, -13.78 to -11.61). The comparison with semaglutide 2.4 mg indicated a modest and uncertain additional reduction in HbA1c of -0.21 percentage points (95% CrI, -0.62 to 0.11) but a probable additional body weight reduction of -5.84 percentage points (95% CrI, -10.08 to -2.15).
Interpretation
The findings indicate that CagriSema provides substantial benefits in glycaemic control and body weight compared to placebo. While the HbA1c reduction is statistically significant, the effect size compared to semaglutide is small and uncertain, suggesting limited clinical relevance. The increased risk of gastrointestinal adverse events and discontinuation raises concerns about the tolerability of CagriSema, which should be considered when evaluating its use in practice.
Key findings
- -1.87 percentage points HbA1c reduction vs placebo (95% CrI, -2.08 to -1.62)
- -12.69 percentage points body weight change vs placebo (95% CrI, -13.78 to -11.61)
- -0.21 percentage points additional HbA1c reduction vs semaglutide 2.4 mg (95% CrI, -0.62 to 0.11)
- -5.84 percentage points additional body weight reduction vs semaglutide 2.4 mg (95% CrI, -10.08 to -2.15)
- RR of gastrointestinal adverse events vs placebo is 2.27 (95% CrI, 1.81 - 3.00)
- RR of adverse-event-related discontinuation vs placebo is 3.16 (95% CrI, 1.50 to 6.87)
Limitations
- small n in individual trials
- uncertainty in gastrointestinal tolerability estimates
- short follow-up duration
- potential for publication bias